Adjunctive vitamin d2 supplement in patient with allergen-specific immunotherapy randomized, double-blind, placebo-controlled trial

Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation in the Build-up Phase of House Dust Mite-Specific Immunotherapy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20190813001

Enrollment

Registered

2019-08-13

Start date

2018-12-20

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with allergic rhinitis and asthma begin treatment with allergen-specific immunotherapy. Calciferol, Vitamin D2 , allergic rhinitis, asthma, allergen-specific immunotherapy, TNSS score, ACT score, PEFR, Absolute eosinophil

Interventions

Oral vitamin d2 (Calciferol) 20&#44

000 iu 1 capsule on Monday&#44

Wednesday&#44

and Friday,Placebo 1 capsule on Monday&#44

and Friday

Active Comparator Drug,Placebo Comparator Drug

Vitamin D2 (Calciferol) supplement,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with allergic rhinitis and asthma. 2. Patients begin treatment with allergen-specific immunotherapy or Patients that used to treatment with allergen-specific immunotherapy and stop more than 6 months. 3. Patients decided to begin treatment with allergen-specific immunotherapy 4. Patient glad to join in this research and begin treatment with calciferol.

Exclusion criteria

Exclusion criteria: 1. Patients were contrandicated to recieve Calciferol such as allergy. 2. Patients with liver or kidney disease 3. Patients with severe adverse effect from allergen-specfic immunotherapy or calciferol 4. Patients with 25-OH Vitamin D level above 150 ng/mL before start research. 5. Patients with severe or uncontrolled asthma 6. Patients with underlying active heart disease such as Myocardial infarction in 4 weeks. 7. Patients with active malignancy and on going treatment with chemotherapy. 8. Patients with primary and secondary immunodeficiency. 9. Patients were included in the previous research within 30 days. 10.Pregnancy patients at any GA.

Design outcomes

Primary

Measure	Time frame
Clinical score TNSS, ACT, PEFR 10 weeks and 20 weeks Questionnaire	—

Secondary

Measure	Time frame
Laboratory Regulartory T cell, Absolute Eosinophil, IL-10, Der p 1-specific IgE and IgG4 levles 10 weeks and 20 weeks Blood drawing , flow cytometry, ELISA	—

Countries

Thailand

Contacts

Public ContactChirawat Chiewchalermsri

Phramongkutklao hospital

chirawatearth@gmail.com0989683561

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026